Hans J. Hammers

2004–2025 年に発表

別表記: Hans J Hammers

99: 論文数
25,360: 被引用数
60: h 指数
90: i10 指数

被引用数

引用元

国・地域

0%25.3%その他 23.8%

機関

分野

トピック

全論文

並び替え

検索で開く

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 被引用: 5,890
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M. Burke, Gurjyot K. Doshi, Delphine Topart, Stéphane Oudard, Hans J. Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F. Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
著者: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 被引用: 263
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
著者: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 被引用: 780
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen-Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross‐Goupil, Tian Zhang, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stéphane Oudard, Delphine Topart, Hans J. Hammers, Hiroshi Kitamura, David F. McDermott, Adriano da Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles - New England Journal of Medicine 2024 被引用: 285
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 被引用: 939
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
著者: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, Hans J. Hammers, Thomas E. Hutson, Jae‐Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Maroto, Daniel Y.C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, Nizar M. Tannir, Robert J. Motzer - New England Journal of Medicine 2015 被引用: 1,226
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
著者: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 被引用: 337
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
著者: Nizar M. Tannir, Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Sangeeth M. George, Frede Donskov, Michael B. Atkins, Howard Gurney, C.K. Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, Ruowei Jiang, Heshani Desilva, В. Э. Федоров, Chung‐Wei Lee, Robert J. Motzer - Annals of Oncology 2024 被引用: 192
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
著者: Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Margolin, Elizabeth R. Plimack, Alexandre Lambert, Ian M. Waxman, Hans J. Hammers - Journal of Clinical Oncology 2014 被引用: 1,078
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
著者: Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin - Journal of Clinical Oncology 2017 被引用: 508
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
著者: Huafeng Zhang, David Z. Qian, Yee Sun Tan, KangAe Lee, Ping Gao, Yunzhao R. Ren, Sergio Rey, Hans J. Hammers, Daniel Chang, Роберто Пили, Chi V. Dang, Jun O. Liu, Gregg L. Semenza - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 被引用: 616
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
著者: Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans J. Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins - Journal for ImmunoTherapy of Cancer 2019 被引用: 262
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
著者: Linda Chen, Jacqueline Douglass, Lawrence Kleinberg, Xiaobu Ye, Ariel E. Marciscano, Patrick M. Forde, Julie R. Brahmer, Evan J. Lipson, William H. Sharfman, Hans J. Hammers, Jarushka Naidoo, Chetan Bettegowda, Michael Lim, Kristin J. Redmond - International Journal of Radiation Oncology*Biology*Physics 2017 被引用: 327
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
著者: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 被引用: 225
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
著者: Raquibul Hannan, Michael Christensen, Hans J. Hammers, Alana Christie, Brendan Paulman, Dandan Lin, Aurélie Garant, Waddah Arafat, Kevin D. Courtney, I. Alex Bowman, Suzanne Cole, David J. Sher, Chul Ahn, Hak Choy, Robert Timmerman, James Brugarolas - European Urology Oncology 2022 被引用: 80
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
著者: David Cella, Viktor Grünwald, Bernard Escudier, Hans J. Hammers, Saby George, Paul Nathan, Marc‐Oliver Grimm, Brian I. Rini, Justin Doan, Cristina Ivanescu, Jean Paty, Sabeen Mekan, Robert J. Motzer - The Lancet Oncology 2019 被引用: 254
Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer
著者: Raquibul Hannan, Michael Christensen, Alana Christie, Aurélie Garant, Iván Pedrosa, Liliana Robles, Samantha Mannala, Chiachien Wang, Hans J. Hammers, Waddah Arafat, Kevin D. Courtney, I. Alex Bowman, David J. Sher, Chul Ahn, Suzanne Cole, Hak Choy, Robert Timmerman, James Brugarolas - European Urology Oncology 2022 被引用: 68
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination
著者: Channing J. Paller, Michelle A. Rudek, Xian Zhou, William D. Wagner, Tamaro Hudson, Nicole M. Anders, Hans J. Hammers, Donna Dowling, Serina King, Emmanuel S. Antonarakis, Charles G. Drake, Mario A. Eisenberger, Samuel R. Denmeade, Gary L. Rosner, Michael A. Carducci - The Prostate 2015 被引用: 125
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
著者: Nizar M. Tannir, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Michael B. Atkins, Christian Kollmannsberger, Marc‐Oliver Grimm, Yoshihiko Tomita, Brian I. Rini, Ruiyun Jiang, Heshani Desilva, Chung‐Wei Lee, Robert J. Motzer - Journal of Clinical Oncology 2024 被引用: 46
Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database
著者: Nirmish Singla, Ryan Hutchinson, Rashed Ghandour, Yuval Freifeld, Dong Fang, Arthur I. Sagalowsky, Yair Lotan, Aditya Bagrodia, Vitaly Margulis, Hans J. Hammers, Solomon L. Woldu - Urologic Oncology Seminars and Original Investigations 2020 被引用: 126
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
著者: Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer - European Urology 2017 被引用: 251
Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma
著者: Matthew E. Tenold, Praful Ravi, Monika Kumar, I. Alex Bowman, Hans J. Hammers, Toni K. Choueiri, Primo N. Lara - American Society of Clinical Oncology Educational Book 2020 被引用: 67